Treatment of Type 2 Diabetes With Long Acting Basal Insulin in Jordan
Status:
Completed
Trial end date:
2017-11-27
Target enrollment:
Participant gender:
Summary
Primary Objective:
-To assess the change in glycosylated hemoglobin (HbA1c) in uncontrolled Type 2 diabetes
patients on OAD agent in Jordan after 6 months of treatment with basal insulin (Insulin
glargine).
Secondary Objectives:
- To evaluate the percentage of patients achieving target of HbA1c ˂7%.
- To evaluate the change in fasting plasma glucose (FPG).
- To assess the following safety criteria: hypoglycemic events, body weight changes, and
overall safety.
- Describe the titration process: changes in glargine insulin dose at 3 months and 6
months, changes in the titration doses used (if any), and time to reach control.